Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Dr. Reddy’s Laboratories announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection.
read more
Thursday, February 21, 2019
Dr. Reddy’s announced the re-launch of its Buprenorphine and Naloxone Sublingual Film, a therapeutic equivalent generic version of Suboxone sublingual film, in the U.S. market.
read more
Dr. Reddy’s Laboratories has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private, a generics pharmaceutical company.
read more
Dr. Reddy’s Laboratories has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology.
read more
Dr. Reddy’s and its subsidiary, Promius Pharma announced the filing of NDA for its migraine candidate DFN-02 with the FDA.
read more
Wednesday, October 23, 2019
Dr. Reddy’s confirms it initiated a voluntary nationwide recall of all of its ranitidine medications sold in US due to confirmed contamination with NDMA above levels established by the FDA.
read more
Wednesday, February 19, 2020
Dr. Reddy’s Laboratories has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business.
read more
Dr. Reddy’s Laboratories and CHD Bioscience announced a global licensing agreement for the clinical development and commercialization of Dr. Reddy’s Phase III clinical trial candidate, DFA-02.
read more
Wednesday, November 06, 2013
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with Opthea Pty Ltd of Melbourne, Australia.
read more
Thursday, October 31, 2013
Royal DSM, the global Life Sciences and Materials Sciences company, today announced it has signed an agreement with the Sanquin Blood Supply Foundation (Sanquin) for the commercial manufacture of a monoclonal antibody used for the recovery and ...
read more
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM announced today that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in June 2013.
read more
DSM, a global leader in materials science and regenerative medicine, announced today the launch of its cellular therapy development services. Cellular therapies use a patient’s own cells to improve healing of an injury or disease. DSM develops ...
read more
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ,...
read more
PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s ...
read more
Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of ...
read more